Takeda said that the tool evaluates risk for developing complications associated with Crohn's disease and helps support personalized clinical decision-making.
Tempus said that Akesogen's lab provides a range of testing services, including for inherited risk of cancer, microbiome profiling, whole-genome genotyping, and more.
The firm said that in its product pipeline in 2019 it focused on organ transplant and lung health, involving use of its multiplexed research-use TORdx Lung tests.
